Syndax Pharmaceuticals Profit Margin

Syndax Pharmaceuticals (SNDX) currently reports a profit margin of -72.38% as of September 2026. That compares with -279.31% in the prior-year period — up 74.1% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Syndax Pharmaceuticals's profit margin history and peer comparisons.

Syndax Pharmaceuticals's profit margin increased from -279.31% to -72.38% — a 74.1% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Syndax Pharmaceuticals's profit margin of -72.38% is lower than the Healthcare sector average of 9.48%. That is roughly 863.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Syndax Pharmaceuticals's current -72.38% should be judged against Healthcare norms (sector average: 9.48%) and against SNDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -72.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Syndax Pharmaceuticals, and consider following SNDX for alerts when major investors trade the stock.